Glenpoint Centre East 300 Frank W. Burr Blvd. Teaneck, New Jersey, 07666

201-692-9434

CORNEAL COLLAGEN CROSSLINKING

Collagen Crosslinking for Keratoconus Approved:  We are happy to announce FDA approval of corneal collagen crosslinking (CXL) for the treatment of progressive keratoconus.  As medical monitor of the U.S. clinical trials of crosslinking, Dr. Peter Hersh played a central part in crosslinking approval.  At the CLEI Center for Keratoconus, we started the crosslinking procedure in February 2008.  We thank our many patients who participated in the study and are grateful that this important procedure will now be more widely available to keratoconus patients.  If you have any questions, please contact us at 201-883-0505 or email info@vision-institute.com.


Please enjoy the recently published paper authored by Dr. Peter Hersh, medical monitor of the U.S. crosslinking clinical trials. 

United States Multicenter Clinical Trial of Corneal Collagen Crosslinking for Keratoconus Treatment

Click here to read Dr. Hersh's new ebook, a compilation of published articles on Corneal Collagen Crosslinking

CORNEAL COLLAGEN CROSSLINKING (CXL) BACKGROUND

Keratoconus

 

Collagen crosslinking uses ultraviolet (UV) light combined with riboflavin (Vitamin B2).The primary goal of collagen crosslinking in the keratoconic patient is to strengthen and stiffen the corneal fibers in order to decrease the progression of keratoconus, and to decrease the cone steepness in some patients. You can read about the crosslinking study and results in our paper "Corneal Collagen Crosslinking for Keratoconus and Corneal Ectasia".

 

Here at the CLEI Center for Keratoconus, we have been performing crosslinking for over 8 years and have performed over 1000 treatments.

 

THE CROSSLINKING PROCEDURE

Keratoconus CXL is performed at the state of the art CLEI Center for Keratoconus by Dr. Peter Hersh. Anesthesia drops keep you comfortable and a lid retainer prevents you from blinking. The surface epithelial cells of the cornea are then removed and riboflavin drops are administered for 30 minutes. The riboflavin acts both to enhance the crosslinking effect and to protect the rest of the eye from the UV exposure.

The patient then looks at a UV emitting light (wavelength = 365 microns, power = 3.0 mW/cm2) for 30 additional minutes with continued administration of riboflavin drops. At the conclusion of the procedure, a soft contact lens bandage is applied. The contact lens is left in place to improve healing for approximately 5 days and is then removed. Antibiotic and anti-inflammatory drops are used for two weeks afterwards.

If you have an interest or have any questions about collagen crosslinking, please call our office at 201-883-0505 or email info@vision-institute.com.